1. In Vivo
  2. >>Business Strategy

It’s Time For A Billion-Dollar Women's Health Fund

Insights From 2023 Rising Leader And Women’s Health Investor, Jessica Federer

 
• By Lucie Ellis-Taitt

Jessica Federer, former chief digital officer at Bayer, talks to In Vivo about making the jump into investing and why women’s health is a rich and deep market set for change.

women’s health investor summit at the NYSE
Women’s health investor summit at the NYSE, May 2023

Jessica Federer was the first chief digital officer for German big pharma Bayer AG, as well as the first woman to hold that role across the biopharma industry. Now, she is managing partner at Supernode Ventures, investing in early-stage companies with a focus on women’s health.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.